Skip to content
Search AI Powered

Latest Stories

Diabetes patient number and prescription volume on the rise since 2015: NHS

The volume of prescription items for the treatment of diabetes as well as patient numbers have steady risen since 2015, according to latest official figures.

The NHS Business Services Authority said today (Nov 5) that the number of prescription items used mainly to treat diabetes has increased every year between 2015/16 and 2019/20. The number of patients in the same period has also increased but not as much as prescriptions, resulting in a greater number of items per patient in 2019/20 than in previous years.


In a report entitled 'Prescribing for Diabetes England 2015/16 to 2019/20', NHSBSA said the total cost of diabetes drugs prescribed has increased since 2015, due to large increases in costs of antidiabetic drugs and insulin.

These increases are larger than both the number of items prescribed and the number of patients which has resulted in increased cost per person in 2019/20 than in previous years, the report added.

Antidiabetic drugs have remained the most prescribed of the diabetes items. Prescribing for all categories increased between 2018/19 and 2019/20, except for diabetic diagnostic and monitoring agents, which decreased by 6 per cent.

Overall demographics of patients too have remained steady over the last five years with the median age remaining constant at 64 years.

Similarly, the gender split has remained steady with 55 per cent male as opposed to 45 per cent female patients since 2015/16.

Areas of greatest deprivation have the highest number of patients per population receiving diabetes medicines, with 8.6 per cent of people in the most deprived areas receiving diabetes medication, compared to 3.4 per cent of people in the least deprived parts of the country.

This pattern is replicated at drug levels too, with 7.5 per cent of the population in the most deprived areas receiving antidiabetic drugs, in comparison with 2.9 per cent people of in the least deprived areas, the report concluded.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
It is official: Opella is now a standalone company

Opella launches as an independent company to redefine the future of self-care.

Photo credit: gettyimages

Opella becomes standalone company as Sanofi-CD&R deal closes

Opella has officially become a standalone company, following the completion of Sanofi’s sale of a controlling 50.0% stake to private equity firm Clayton, Dubilier & Rice (CD&R).

Sanofi retains a significant shareholding with a 48.2% stake while Bpifrance holds the remaining 1.8% stake.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less